ROR1, an embryonic protein with an emerging role in cancer biology.
10.1007/s13238-014-0059-7
- Author:
Nicholas BORCHERDING
1
;
David KUSNER
;
Guang-Hui LIU
;
Weizhou ZHANG
Author Information
1. Department of Pathology, College of Medicine, University of Iowa, Iowa City, IA, 52242, USA.
- Publication Type:Journal Article
- MeSH:
Animals;
Antineoplastic Agents;
pharmacology;
Embryonic Development;
Humans;
Immunotherapy;
Molecular Targeted Therapy;
Neoplasms;
drug therapy;
enzymology;
Receptor Tyrosine Kinase-like Orphan Receptors;
physiology
- From:
Protein & Cell
2014;5(7):496-502
- CountryChina
- Language:English
-
Abstract:
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a member of the ROR family consisting of ROR1 and ROR2. RORs contain two distinct extracellular cysteine-rich domains and one transmembrane domain. Within the intracellular portion, ROR1 possesses a tyrosine kinase domain, two serine/threonine-rich domains and a proline-rich domain. RORs have been studied in the context of embryonic patterning and neurogenesis through a variety of homologs. These physiologic functions are dichotomous based on the requirement of the kinase domain. A growing literature has established ROR1 as a marker for cancer, such as in CLL and other blood malignancies. In addition, ROR1 is critically involved in progression of a number of blood and solid malignancies. ROR1 has been shown to inhibit apoptosis, potentiate EGFR signaling, and induce epithelial-mesenchymal transition (EMT). Importantly, ROR1 is only detectable in embryonic tissue and generally absent in adult tissue, making the protein an ideal drug target for cancer therapy.
